Article
Multidisciplinary Sciences
Ryota Ogura, Saya Ito, Takashi Ueda, Yusuke Gabata, Satoshi Sako, Yuta Inoue, Takeshi Yamada, Hirotaka Konishi, Atsuko Fujihara, Osamu Ukimura
Summary: This study evaluated a practical method to monitor the cancer status at the circulating cell-gene level and determine the efficacy of drug therapy in patients with metastatic bladder cancer.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Yvonne L. E. Ang, Xiaotian Zhao, Thanyanan Reungwetwattana, Byoung-Chul Cho, Bin-Chi Liao, Rebecca Yeung, Herbert H. Loong, Dong-Wan Kim, James Chih-Hsin Yang, Sun Min Lim, Myung-Ju Ahn, Se-Hoon Lee, Thitiporn Suwatanapongched, Kanchaporn Kongchauy, Qiuxiang Ou, Ruoying Yu, Bee Choo Tai, Boon Cher Goh, Tony S. K. Mok, Ross A. Soo
Summary: Non-invasive blood testing for T790M mutation can guide the treatment of lung cancers with EGFR gene mutations using Osimertinib, and has good outcomes. Levels of DNA markers in the blood can predict treatment outcomes.
Article
Chemistry, Medicinal
Haojie Dong, Xiuquan Ye, Yasheng Zhu, Hao Shen, Hongtao Shen, Weijiao Chen, Minghui Ji, Mingming Zheng, Keren Wang, Zeyu Cai, Haopeng Sun, Yibei Xiao, Peng Yang
Summary: In this study, a series of Osimertinib derivatives were designed as fourth-generation inhibitors targeting Osimertinib-resistant NSCLC. The top candidate D51 showed potent inhibition against EGFR mutants, selectivity against wild-type forms, and favorable in vivo druggability.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Oncology
Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, In-Jae Oh, Young-Chul Kim
Summary: The study demonstrates that osimertinib is effective in the first-line treatment of metastatic NSCLC patients harboring activating EGFR mutations in both ctDNA and tumor DNA, with particularly favorable outcomes in patients with ex19del mutations in terms of objective response rate and progression-free survival.
CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Kazuko Sakai, Takayuki Takahama, Mototsugu Shimokawa, Koichi Azuma, Masayuki Takeda, Terufumi Kato, Haruko Daga, Isamu Okamoto, Hiroaki Akamatsu, Shunsuke Teraoka, Akira Ono, Tatsuo Ohira, Toshihide Yokoyama, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Kazuto Nishio
Summary: The WJOG8815L phase II clinical study examined the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA from NSCLC patients receiving osimertinib treatment. Results showed a decrease in sensitizing and T790M-EGFR mutant fractions during treatment, with a rebound of sensitizing EGFR MF observed at disease progression or treatment discontinuation. Significant differences in response rates and progression-free survival were observed based on sensitizing EGFR MF grouping at cycle 4.
MOLECULAR ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Dan Yan, Justus M. Huelse, Dmitri Kireev, Zikang Tan, Luxiao Chen, Subir Goyal, Xiaodong Wang, Stephen Frye, Madhusmita Behera, Frank Schneider, Suresh S. Ramalingam, Taofeek Owonikoko, H. Shelton Earp, Deborah DeRyckere, Douglas K. Graham
Summary: Acquired resistance is inevitable in non-small cell lung cancers (NSCLCs) treated with osimertinib (OSI). Activation of MERTK is associated with OSI resistance and inhibition of MERTK kinase can resensitize resistant cells to OSI.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Review
Oncology
Ming Yu, Yu Zhu, Lichen Teng, Jialin Cui, Yajuan Su
Summary: This article highlights the challenges in early screening and treatment for ovarian cancer, while demonstrating the important value of cfDNA/ctDNA as a liquid biopsy marker in the diagnosis, monitoring, and prognosis of ovarian cancer, with potential to be a focus of future research.
JOURNAL OF ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Shen Zhao, Wu Zhuang, Baohui Han, Zhengbo Song, Wei Guo, Feng Luo, Lin Wu, Yi Hu, Huijuan Wang, Xiaorong Dong, Da Jiang, Mingxia Wang, Liyun Miao, Qian Wang, Junping Zhang, Zhenming Fu, Yihua Huang, Chunwei Xu, Longyu Hu, Lei Li, Rong Hu, Yang Yang, Mengke Li, Xiugao Yang, Li Zhang, Yan Huang, Wenfeng Fang
Summary: This study reports the safety and preliminary efficacy of a phase I clinical trial (JMT101) combining an anti-EGFR antibody with EGFR-TKI in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions. The combination therapy demonstrated good tolerability and promising efficacy in patients.
NATURE COMMUNICATIONS
(2023)
Article
Cell Biology
Shigetoshi Nishihara, Toshimitsu Yamaoka, Fumihiro Ishikawa, Tohru Ohmori, Koichi Ando, Sojiro Kusumoto, Yasunari Kishino, Ryo Manabe, Yuki Hasebe, Hironori Sagara, Hitoshi Yoshida, Junji Tsurutani
Summary: This study investigated the mechanisms of osimertinib resistance in NSCLC cells and identified diverse resistance mechanisms. The findings provide insights for developing novel therapeutic strategies for NSCLC.
Editorial Material
Medicine, General & Internal
Mary E. Norton
Summary: The 2022 Lasker-DeBakey Clinical Medical Research Award is awarded to Yuk Ming Dennis Lo for his discovery of fetal DNA in the maternal circulation, which has revolutionized prenatal screening.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Motohiro Tamiya, Akihiro Tamiya, Norio Okamoto, Yoshihiko Taniguchi, Kazumi Nishino, Shinji Atagi, Tomonori Hirashima, Fumio Imamura, Toru Kumagai, Hidekazu Suzuki
Summary: In this study, it was found that treating T790M-positive NSCLC patients with afatinib followed by osimertinib may lead to better outcomes. The T790M ratio was significantly correlated with osimertinib response, and there was no significant difference in T790M ratio between the Afa group and 1st-G group.
SCIENTIFIC REPORTS
(2021)
Review
Immunology
Yunhui Li, Bin Liang
Summary: This study analyzed the levels of circulating dd-cfDNA in different types of graft rejection and evaluated its diagnostic potential in predicting graft rejection after lung transplantation. The results showed that circulating dd-cfDNA levels were significantly higher in graft rejection, ACR, and AMR compared to non-rejection. Circulating dd-cfDNA could be used as a non-invasive biomarker to distinguish patients with graft rejection from normal stable controls.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Yoojoo Lim, Sheehyun Kim, Jun-Kyu Kang, Hwang-Phill Kim, Hoon Jang, Hyojun Han, Hyoki Kim, Min Jung Kim, Kyung-Hun Lee, Seung-Bum Ryoo, Ji Won Park, Seung-Yong Jeong, Kyu Joo Park, Gyeong Hoon Kang, Sae-Won Han, Tae-You Kim
Summary: A study on ctDNA analysis in mCRC patients revealed that specific gene mutations are closely associated with disease progression and treatment outcomes. Particularly, changes in VAF can serve as predictive indicators for early treatment response and disease progression.
SCIENTIFIC REPORTS
(2021)
Article
Genetics & Heredity
Madonna R. Peter, Misha Bilenky, Yuliang Shi, Jiajie Pu, Shivani Kamdar, Aaron R. Hansen, Neil E. Fleshner, Srikala S. Sridhar, Anthony M. Joshua, Martin Hirst, Wei Xu, Bharati Bapat
Summary: This study identifies a methylated cfDNA marker panel associated with androgen treatment resistance in metastatic prostate cancer, which could aid in its clinical management.
Article
Chemistry, Analytical
Young Jun Kim, Young-Ho Cho, Junhong Min, Sae-Won Han
Summary: The study introduces CSID hydrogel immunospheres for the isolation of CTCs and CTXs, showing stability in biological buffers and easy retrieval of circulating markers. The immunospheres were successfully modified with antibodies and applied to clinical blood samples, demonstrating their potential as a time-efficient assay platform in liquid biopsy.
ANALYTICAL CHEMISTRY
(2021)
Letter
Oncology
M. Del Re, C. Omarini, L. Diodati, M. Palleschi, I. Meattini, S. Crucitta, G. Lorenzini, C. Isca, A. Fontana, L. Livi, F. Piacentini, S. Fogli, U. De Giorgi, R. Danesi
Review
Oncology
Stefania Crucitta, Federico Cucchiara, Ron Mathijssen, Joaquin Mateo, Agnes Jager, Arjen Joosse, Antonio Passaro, Ilaria Attili, Iacopo Petrini, Ron van Schaik, Romano Danesi, Marzia Del Re
Summary: Molecular heterogeneity is a characteristic of tumor evolution and adaptation, and it is a major cause of drug resistance. The pharmacological characteristics of a drug and the selective pressure of treatments influence the development of resistance mechanisms. This review focuses on tumor heterogeneity and its relation to resistance to targeted therapy, providing guidance for new drug development and therapeutic combinations.
CANCER TREATMENT REVIEWS
(2022)
Article
Oncology
Rosanna Ruggiero, Barbara Stelitano, Federica Fraenza, Gabriella di Mauro, Cristina Scavone, Liberata Sportiello, Concetta Rafaniello, Raffaella Di Napoli, Romano Danesi, Marzia Del Re, Francesco Rossi, Annalisa Capuano
Summary: This study described the observed ICI-related neurological immune-related adverse drug reactions (NirADRs) in the European clinical practice, primarily associated with anti-PD-1 agents and more common in male patients. Some events had unfavorable outcomes, including fatal consequences, emphasizing the need for further research to monitor the neurologic safety profile of ICIs.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
P. Conte, P. A. Ascierto, G. Patelli, R. Danesi, A. Vanzulli, F. Sandomenico, P. Tarsia, A. Cattelan, A. Comes, M. De Laurentiis, A. Falcone, D. Regge, L. Richeldi, S. Siena
Summary: Drug-induced interstitial lung disease (DIILD) is a form of interstitial lung disease resulting from exposure to drugs causing inflammation and possibly interstitial fibrosis. Antineoplastic drugs are the primary cause of DIILD, but there are currently no specific guidelines on the diagnosis and treatment of DIILD caused by anticancer drugs.
Article
Oncology
Marzia Del Re, Stefania Crucitta, Claudia Omarini, Irene Bargagna, Marta Mongillo, Michela Palleschi, Stefania Stucci, Icro Meattini, Raffaella D'Onofrio, Giulia Lorenzini, Pamela Biondani, Ugo De Giorgi, Camillo Porta, Lorenzo Livi, Salvatore Natalizio, Andrea Fontana, Elena Giontella, Lucia Angelini, Stefano Fogli, Romano Danesi
Summary: This study found that the concomitant use of proton-pump inhibitors does not compromise the efficacy of ribociclib in a real-life setting.
Review
Oncology
Alfredo Berruti, Sergio Bracarda, Orazio Caffo, Enrico Cortesi, Rolando D'Angelillo, Marzia Del Re, Gaetano Facchini, Giovanni Pappagallo, Giuseppe Procopio, Roberto Sabbatini, Daniele Santini
Summary: Non-metastatic castration resistant prostate cancer (nmCRPC) refers to a clinical setting where patients treated with ADT have rising levels of PSA but no detectable metastases on conventional imaging. Recent phase III trials have shown that adding a next-generation androgen receptor targeted agent (ARTA) to ADT delays the development of metastases and improves overall survival in nmCRPC patients. Novel imaging techniques and potential tumor biomarkers are changing the diagnosis and management of nmCRPC.
CANCER TREATMENT REVIEWS
(2023)
Review
Oncology
Alberto Lapini, Orazio Caffo, Giario Natale Conti, Giovanni Pappagallo, Marzia Del Re, Rolando Maria D'Angelillo, Ettore Domenico Capoluongo, Francesca Castiglione, Matteo Brunelli, Roberto Iacovelli, Ugo De Giorgi, Sergio Bracarda
Summary: The recent approval of PARP inhibitors for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA mutations has brought the possibility of targeted treatment in this disease. However, this raises questions regarding the management of prostate cancer, including the timing and method of detecting BRCA mutations, therapeutic implications, and family screening. The Italian Society for Uro-Oncology (SIUrO) organized a Consensus Conference to develop suggestions for clinicians managing prostate cancer patients, involving major Italian scientific societies.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Immunology
Rosanna Ruggiero, Nunzia Balzano, Raffaella Di Napoli, Federica Fraenza, Ciro Pentella, Consiglia Riccardi, Maria Donniacuo, Marina Tesorone, Romano Danesi, Marzia Del Re, Francesco Rossi, Annalisa Capuano
Summary: Although immunotherapy has revolutionized cancer treatment, it can also lead to adverse events involving the peripheral nervous system. Through analyzing data from the European real-world context, we found that immune checkpoint inhibitors are associated with peripheral neuropathies, which can have serious consequences for patients' safety and quality of life.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Stefania Crucitta, Martina Ruglioni, Giulia Lorenzini, Irene Bargagna, Giovanna Irene Luculli, Irene Albanese, Diana Bilancio, Francesca Patane, Andrea Fontana, Romano Danesi, Marzia Del Re
Summary: This study investigated the clinical benefit of CDK4/6 inhibitors (CDK4/6i) in ESR1 mutant HR+ metastatic breast cancer (mBC) patients as first- or second-line therapy. Analysis of ESR1 mutations in circulating free DNA showed that it was an independent predictive factor of clinical recurrence in the adjuvant setting. The results suggest that CDK4/6i can overcome ESR1-dependent resistance.
Article
Oncology
Alessandro Russo, Katherine A. Scilla, Ranee Mehra, Allison Gittens, Michael G. McCusker, Diego de Miguel-Perez, Jorge E. Gomez, Ariel Peleg, Marzia Del Re, Christian D. Rolfo
CLINICAL LUNG CANCER
(2023)
Article
Gastroenterology & Hepatology
Giorgio Guglielmi, Stefania Crucitta, Lorenzo Bertani, Martina Ruglioni, Giovanni Baiano Svizzero, Linda Ceccarelli, Marzia Del Re, Romano Danesi, Francesco Costa, Stefano Fogli
Summary: This study suggests that the expression levels of circulating let-7e and miR-126 may serve as biomarkers for predicting clinical remission in Crohn's disease patients treated with anti-TNF-& alpha; biologics.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Oncology
Federico Cucchiara, Stefania Crucitta, Iacopo Petrini, Diego de Miguel Perez, Martina Ruglioni, Eleonora Pardini, Christian Rolfo, Romano Danesi, Marzia Del Re
Summary: Gene-network analysis identified mutations in chromatin remodeling and cell-to-cell signaling pathways as predictive biomarkers for response to immune checkpoint inhibitors in non-small cell lung cancer. These predictive signatures performed best in patients receiving first-line immunotherapy and those receiving combined immune checkpoint inhibitors.
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Review
Oncology
Guido Giordano, Gaia Griguolo, Matteo Landriscina, Icro Meattini, Francesco Carbone, Augusto Leone, Marzia Del Re, Stefano Fogli, Romano Danesi, Antonio Colamaria, Maria Vittoria Dieci
Summary: This article discusses the management strategies for HER2+ breast cancer brain metastases. Despite some therapeutic advances, there is still a need for more effective systemic treatment options. The article summarizes current and future locoregional and systemic strategies and proposes an evidence-based treatment algorithm.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)